EcoDrugPlus

Neurotrophic Receptor Tyrosine Kinase 3

Ensembl ID : ENSABRG00000021879
Gene Symbol: NTRK3
1 Cross references
271 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicastrin

Ensembl ID : ENSABRG00000004636
Gene Symbol: NCSTN
1 Cross references
204 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSABRG00000023141
Gene Symbol: NAMPT
1 Cross references
235 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nischarin

Ensembl ID : ENSABRG00000020062
Gene Symbol: NISCH
1 Cross references
207 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nitric Oxide Synthase 2

Ensembl ID : ENSABRG00000015562
Gene Symbol: NOS2
1 Cross references
168 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Notch Receptor 1

Ensembl ID : ENSABRG00000021760
Gene Symbol: NOTCH1
1 Cross references
268 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 1

Ensembl ID : ENSABRG00000010226
Gene Symbol: NFKB1
1 Cross references
205 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Factor Kappa B Subunit 2

Ensembl ID : ENSABRG00000001716
Gene Symbol: NFKB2
1 Cross references
124 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 3

Ensembl ID : ENSABRG00000004173
Gene Symbol: NR1H3
1 Cross references
392 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 1 Group H Member 4

Ensembl ID : ENSABRG00000013877
Gene Symbol: NR1H4
1 Cross references
388 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 1

Ensembl ID : ENSABRG00000016405
Gene Symbol: NR3C1
1 Cross references
280 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Nuclear Receptor Subfamily 3 Group C Member 2

Ensembl ID : ENSABRG00000014515
Gene Symbol: NR3C2
1 Cross references
214 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).